Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study

被引：34

作者：

Kita, Mariko ^{[1
]}

Fox, Robert J. ^{[2
]}

Phillips, J. Theodore ^{[3
]}

Hutchinson, Michael ^{[4
]}

Havrdova, Eva ^{[5
]}

Sarda, Sujata P. ^{[6
]}

Agarwal, Sonalee ^{[6
]}

Kong, Jessica ^{[6
]}

Zhang, Annie ^{[6
]}

Viglietta, Vissia ^{[6
]}

Sheikh, Sarah I. ^{[6
]}

Seidman, Emily ^{[7
]}

Dawson, Katherine T. ^{[6
]}

机构：

[1] Virginia Mason Med Ctr, Neurosci Inst, Seattle, WA 98101 USA

[2] Cleveland Clin, Mellen Ctr Multiple Sclerosis Treatment & Res, Dept Neurol, Cleveland, OH 44106 USA

[3] Baylor Inst Immunol Res, Multiple Sclerosis Program, Dallas, TX USA

[4] St Vincents Univ Hosp, Dept Neurol, Dublin 4, Ireland

[5] Charles Univ Prague, Fac Med 1, Dept Neurol, Prague, Czech Republic

[6] Biogen Idec Inc, Cambridge, MA USA

[7] CircleSci, Tytherington, England

来源：

MULTIPLE SCLEROSIS JOURNAL | 2014年 / 20卷 / 02期

关键词：

Multiple sclerosis; relapsing-remitting; BG-12; dimethyl fumarate; quality of life; glatiramer acetate; randomized controlled trial; PLACEBO-CONTROLLED PHASE-3; ORAL BG-12;

D O I：

10.1177/1352458513507818

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Multiple sclerosis (MS) has a significant impact on health-related quality of life (HRQoL) with symptoms adversely affecting many aspects of everyday living. BG-12 (dimethyl fumarate) demonstrated significant efficacy in the phase III studies DEFINE and CONFIRM in patients with relapsing-remitting MS. In CONFIRM, HRQoL was worse in patients with greater disability at baseline, and who relapsed during the study, and improved with BG-12 treatment. Mean Short Form-36 Physical Component Summary scores for BG-12 increased over 2 years and scores for placebo decreased. Coupled with clinical and neuroradiological benefits, these HRQoL results further support BG-12 as an effective oral treatment for relapsing MS.

引用

页码：253 / 257

页数：5

共 50 条

[21] Gastrointestinal Tolerability Events in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Treated with Oral Bg-12 (Dimethyl Fumarate) in Define and Confirm
Bar-Or, A.
Selmaj, K.
Gold, R.
Fox, R. J.
Havrdova, E.
Kurukulasuriya, N. C.
Pace, A.
Novas, M.
Meltzer, L.
Hotermans, C.
Dawson, K. T.
Phillips, J. T.
MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (12) : 1840 - 1841
[22] Interim analysis of quality of life in patients with relapsing remitting multiple sclerosis treated with BG-12 (dimethyl fumarate) in the ENDORSE study
Kita, M.
Fox, R. J.
Gold, R.
Giovannoni, G.
Phillips, J. T.
Sarda, S. P.
Kong, J.
Zhang, R.
Viglietta, V.
Sheikh, S. I.
Kappos, L.
MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 530 - 530
[23] Health-related quality of life in relapsing remitting multiple sclerosis (RRMS) patients treated with placebo or BG-12 (dimethyl fumarate): comparison with other medical conditions
Sarda, S.
Phillips, G.
Gaebler, J. A.
Kurukulasuriya, N. C.
MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 290 - 290
[24] Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study
Bar-Or, Amit
Gold, Ralf
Kappos, Ludwig
Arnold, Douglas L.
Giovannoni, Gavin
Selmaj, Krzysztof
O'Gorman, John
Stephan, Monica
Dawson, Katherine T.
JOURNAL OF NEUROLOGY, 2013, 260 (09) : 2297 - 2305
[25] Safety and Tolerability of BG-12 in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Analyses From the CONFIRM Study
Phillips, J. Theodore
Fox, Robert
Miller, David
Kita, Mariko
Hutchinson, Michael
Havrdova, Eva
Raghupathi, Kartik
Yuan, Huixing
Novas, Mark
Viglietta, Vissia
Dawson, Katherine
NEUROLOGY, 2012, 78
[26] An integrated analysis of the clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis from the phase 3 DEFINE and CONFIRM studies
Fox, R. J.
Miller, D. H.
Phillips, J. T.
Arnold, D. L.
Selmaj, K.
Yang, M.
Zhang, R.
Dawson, K. T.
Viglietta, V.
Sheikh, S. I.
Gold, R.
JOURNAL OF NEUROLOGY, 2013, 260 : S74 - S74
[27] Effect of BG-12 in Subgroups of Patients with Relapsing-Remitting Multiple Sclerosis: Findings from the DEFINE Study
Bar-Or, Amit
Gold, Ralf
Kappos, Ludwig
Arnold, Douglas
Giovannoni, Gavin
Selmaj, Krzysztof
O'Gorman, John
Stephan, Monica
Dawson, Katherine
NEUROLOGY, 2012, 78
[28] Efficacy of Oral BG-12 (Dimethyl Fumarate) in Patients Newly Diagnosed with Relapsing-Remitting Multiple Sclerosis (RRMS): Integrated Analysis of DEFINE and CONFIRM
Gold, R.
Giovannoni, G.
Phillips, J. T.
Fox, R. J.
Rana, J.
Zhang, A.
Meltzer, L.
Kurukulasuriya, N. C.
MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (07) : 931 - 932
[29] Effect of BG-12 (Dimethyl Fumarate) in Subgroups of Patients with Relapsing-Remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies
Bar-Or, Amit
Fox, Robert
Gold, Ralf
Miller, David
Arnold, Douglas
O'Gorman, John
Yang, Minhua
Sheikh, Sarah
Viglietta, Vissia
Dawson, Katherine
Hutchinson, Michael
NEUROLOGY, 2013, 80
[30] Effect of BG-12 (dimethyl fumarate) in newly diagnosed relapsing remitting multiple sclerosis (RRMS) patients from the DEFINE and CONFIRM studies
Gold, R.
Giovannoni, G.
Phillips, J. T.
Fox, R. J.
Zhang, A.
Meltzer, L.
Kurukulasuriya, N. C.
MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 453 - 454

← 1 2 3 4 5 →